Gingyo-San Enhances Immunity and Potentiates Infectious Bursal Disease Vaccination by Hung, Che-Ming et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 238208, 10 pages
doi:10.1093/ecam/nep021
Original Article
Gingyo-SanEnhancesImmunityandPotentiates Infectious
BursalDisease Vaccination
Che-Ming Hung,1,2 Chia-Chou Yeh,3 Kowit-Yu Chong,4 Hsiao-Ling Chen,5 Jiun-Yu Chen,2
Shung-TeKao,6 Chih-ChingYen,2,6 Ming-HsienYeh,3 Maw-SunLin,2 andChuan-MuChen2,6
1Animal Industry Division, Livestock Research Institute, Council of Agriculture, Tainan 712, Taiwan
2Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan
3Department of Chinese Medicine, Buddhist Dalin Tzu Chi General Hospital, Chia-Yi 622, Taiwan
4Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Tao-Yuan 333, Taiwan
5Department of Molecular Biotechnology, Da-Yeh University, Changhwa 515, Taiwan
6China Medical University Hospital, Taichung 404, Taiwan
Correspondence should be addressed to Chuan-Mu Chen, chchen1@dragon.nchu.edu.tw
Received 16 July 2008; Accepted 28 January 2009
Copyright © 2011 Che-Ming Hung et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The purpose of the present study was to investigate the eﬀects of Gingyo-san (GGS), a traditional Chinese medical formula, on
peripheral lymphocyte proliferation and serum antibody titers in chickens vaccinated against the infectious bursal disease (IBD)
virus. Treatment groups were fed one of three doses of GGS in their diet (0.5%, 1.0% and 2.0%, w/w), and the IBD vaccine
was administered at 1 and 3 weeks of age. At Weeks 8, 12 and 16, changes in serum IBD antibody titers were measured via the
micro-method and T cell proliferation. In gene expression experiments, GGS-treated peripheral T lymphocytes were stimulated
with concanavalin A (ConA) for 24h. The mRNA expression of interleukin-2 (IL-2), interferon-γ (IFN-γ), interleukin-4 (IL-4)
and interleukin-12 (IL-12) was determined using a semi-quantitative RT-PCR assay. The results showed that a low dose of GGS
could signiﬁcantly raise the antibody titers. Medium and high doses of GGS enhanced IL-2 and IFN-γ production. GGS altered
the expression of IL-4 and IL-12 in T lymphocytes. CD4+ T lymphocyte development was also skewed towards the Th1 phenotype.
GGS enhanced cell-mediated immunity and augmented the eﬀects of IBD vaccination in strengthening subsequent anti-viral
responses.
1.Introduction
Many traditional Chinese medicines (TCM) and their ingre-
dients have been reported to enhance immunity [1–3], and
they have great potential in many practical applications.
Immunomodulation is an important process for infectious
diseases, especially viral diseases. These diseases result in
huge losses in the domestic animal and poultry industries
[4]. Some infectious diseases remain hard to control due
to the heterogeneity of microorganisms, the inferior quality
or improper storage and transport of vaccines, and the
occurrence of immunosuppressive diseases. The use of
an immunopotentiator with a vaccine could improve the
eﬃcacy and decrease the toxicity of vaccination [5].
Infectious bursal disease (IBD) has a sudden onset with
a short incubation period (2-3 days). Morbidity is usually
100%, but mortality varies depending on the virus strain
[4, 6, 7]. The IBD virus is ubiquitous, is resistant to a variety
of disinfectants, and is environmentally stable. Chickens are
widely exposed to the IBD virus worldwide, which leads
to multi-billion dollar losses in the poultry industry [8].
Serological evidence of natural infection with the virus
showed infection levels of 58.6% in Taiwan [9]. Strategies to
control IBD are largely based on vaccination programmes.
In TCM, Gingyo-san (GGS), is a crude drug containing
extracts from 10 medicinal plants. In TCM therapy, GGS
is frequently used to treat pulmonary disorders including
the common cold and bronchial infections [2]. Experiments
conducted in Japan have revealed that GGS has antipyretic
and antiviral eﬀects [10, 11]. Pharmacological studies of
GGS indicate that it is eﬀective at alleviating fever, relieving
pain, counteracting hypersusceptibility and counteracting2 Evidence-Based Complementary and Alternative Medicine
bacterial and viral infections [12]. In animal trials, GGS
also exhibited signiﬁcant therapeutic eﬀects on bacterial and
viral infections in mice [13]. In addition, two components
identiﬁedfromGGSwereshowntoexhibitantiviralactivities
in mice infected with the inﬂuenza virus [11, 14]. Recently, it
has been reported that GGS exerts an immunomodulatory
eﬀect during acute respiratory distress syndrome (ARDS),
through the down-regulation of inﬂammatory cytokines and
the up-regulation of anti-inﬂammatory cytokines [2]. The
use of GGS in feed additives as part of a preventative pro-
gramme has been implemented on domestic farms in China.
In this study, we investigated the possibility of using GGS
as an immune stimulator to enhance peripheral lymphocyte
proliferation and serum antibody titers in chickens vacci-
nated against the IBD virus. The dose-dependent responses
of immune enhancement to GGS were also evaluated.
2. Methods
2.1. Preparation of GGS Extract. Medicinal plants were
provided by Koda Pharmaceutics Ltd (Taoyuan, Taiwan)
for the preparation of the GGS extract. GGS is commer-
cially available in Taiwan and Japan. The preparation is a
mixture of 10 crude plant ingredients: Lonicera japonica
Thunb. (herb. no. 10802; Caprifoliaceae), Forsythia suspensa
Thunb. (herb. no. 11005; Oleaceae), Mentha haplocalyx Briq.
(herb. no. 11604; Lamiaceae), Schizonepeta tenuifolia Briq.
(herb. no. 11002; Lamiaceae), Glycine max Merr. (herb.
no. 11105; Fabaceae), Glycyrrhiza uralensis Fisch. (herb. no.
10503; Fabaceae), Platycodon grandiﬂorum Jacq. (herb. no.
11004; Campanulaceae), Lophatherum gracile Brongn. (herb.
no. 11106; Poaceae), Arctium lappa L. (herb. no. 10404;
Asteraceae) and PhragmitescommunisTrin. (herb. no. 12001;
P oaceae), at a ratio of 10:10:4:4:5:5:6:5:6:10. The
voucher specimen and method of extraction and analysis of
GGS were as described previously [2]. The extract was dis-
solved in pyrogen-free isotonic saline (YF Chemical, Taipei,
Taiwan) and ﬁltered through a 0.2mm ﬁlter (Microgen,
Laguna Hills, CA, USA) before use. The high-performance
liquid chromatography (HPLC) chromatogram of the GGS
for quality control is shown in Figure 1.
2.2. Reagents. RPMI-1640 medium (Roswell Park Memo-
rial Institute-1640 medium; GIBCO Invitrogen, Carlsbad,
CA), supplemented with benzylpenicillin (100IUmL−1)
and streptomycin (100IUmL−1), was used for in vitro
cell culture, washing and re-suspending cells, and dilut-
ing the mitogen [15]. Concanavalin A (ConA) (Sigma
Chemicals, St Louis, MO) was dissolved in the RPMI-1640
medium to a ﬁnal concentration of 0.025mgmL−1.3 - ( 4 ,
5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
(MTT, Amersco Inc., Solon, OH) was dissolved in calcium-
andmagnesium-free(CMF)phosphate-buﬀeredsaline(PBS,
pH 7.4) to achieve a concentration of 5mgmL−1. These
reagents were ﬁltered through a 0.22μm ﬁlter [16, 17]. The
ConA solution was stored at −20◦C and the MTT solution
and RPMI-640 media were stored at 4◦C. The lymphocyte
separationmedium(Ficoll-Hypaque)anddimethylsulphox-
ide (DMSO) were purchased from Sigma Chemicals.
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Figure 1: HPLC chromatogram of GGS. The solution of GGS
was prepared by dissolving it in pyrogen-free isotonic saline
(10mg/100mL). The major active compound of chlorogenic acid
(0.081mgmL−1) was detected at 10.77min retention time. The
injection volume was 10μL, and the ﬂow rate was 1.0mLmin−1.
2.3. Animals. One-day-old Taiwanese broilers were pur-
chased from the Livestock Research Institute and reared in
concrete ﬂoor pens (1.8m×1.8m per pen) padded with
rice hull litter in an open-sided growing house until 16
weeks of age. The chickens were fed the basal corn-soybean
meal diets based on the guidelines suggested by National
Research Centre (NRC) [18] and the Extension Booklet
for the Taiwan country broiler [19]; these guidelines were
formulated to meet the nutritional requirements for Taiwan
country broilers at diﬀerent stages of the life cycle. Feed and
water were supplied ad libitum.A l le x p e r i m e n t a lp r o c e d u r e s
were approved by the Institutional Animal Care and Use
Committee of the Livestock Research Institute.
2.4. Experimental Design. Forty chickens were randomly
divided into four groups containing equal numbers of birds
of similar body weights (the average BW was 32g). Group
1 was the medicine-free control. Groups 2–4 were fed
GGS powder at one of three concentrations: 0.5% (w/w,
low dosage), 1% (medium dosage) and 2% (high dosage),
respectively. The IBD vaccine was administered twice at
14-day intervals. The ﬁrst vaccine (Bursine-2, Fort Dodge
Animal Health Inc., Charles, IA) was orally administered
at 1 week of age and the second (IBD BLEN, Merial
Select Inc., Gainesville, GA) at 3 weeks of age. At Weeks
8, 12 and 16, six chickens were sampled randomly from
each group for the examination of peripheral lymphocyte
proliferation by the MTT assay. At Weeks 8 and 16, eight
additionalchickensweresampledrandomlyfromeachgroup
for the determination of serum IBD antibody titers using an
enzyme-linked immunosorbent assay (ELISA) kit [20]. The
animal trials were repeated twice.
2.5. Blood Sample Collection and Analysis of Biological Param-
eters. Blood samples were collected from the wing vein with
a24Gneedle.Thetubeswereallowedtostandfor30minand
then centrifuged at 800×g for 15min to isolate the serum.
Thereafter, the sera were stored at –20◦C until analysis. The
concentrations of glutamic oxaloacetic transaminase (GOT)
and glutamic pyruvic transaminase (GTP) were determinedEvidence-Based Complementary and Alternative Medicine 3
by the standardized method of the Japan Society of Clinical
Chemistry (JSCC method kit) (Wako Pure Chem., Osaka,
Japan). Blood urea nitrogen (BUN) contents were deter-
mined by a Urase-glutamate dehydrogenase (Urease-GLDH)
kit (Wako). Creatinine (CRE) levels were determined using a
Jaﬀekit(Wako).Triglycerides(TG)wereassessedusingafree
glycerol blanking kit (Wako). Total cholesterol (T-Chol) was
determined with a Cholesterol Oxidase-HDAOS kit (Wako).
2.6. Jejunum Villous Measurement. Intestinal samples were
taken on the last day of the experiment. The intestinal
sections(2.5cm)fromsixchickenspertreatmentgroupwere
obtained from the jejunum at a position midway between
the Meckel’s diverticulum and the entrance of the bile ducts.
The samples were ﬂushed with saline, ﬁxed in 10% buﬀered
formalin (pH 7.0), embedded with paraﬃn, sectioned into
3μm sections and stained with haematoxylin-eosin (IDEXX
Veterinary Services, Sacramento, CA). For each intestinal
section, 10 randomly selected jejunum villi heights were esti-
mated using Image-Pro-Plus software (Media Cybernetics,
Silver Spring, MD).
2.7. Peripheral Lymphocyte Proliferation Assay. To detect
changes in cellular immunity, a peripheral lymphocyte
proliferation assay was performed, as described previously
[5]. Blood samples (5mL per chicken) were collected and
immediatelytransferredintoasepticcappedtubescontaining
sodium heparin. The samples were diluted with an equal
volume of Hanks’ solution and carefully layered on the
surface of the lymphocyte separation medium. After 15min
centrifugation at 800×g, a white cloud-like band was
observed in the lymphocyte separation solution interface.
The lymphocyte band was collected and washed twice with
RPMI-1640 media without fetal bovine serum (FBS). After
centrifugation, the pellet was resuspended in RPMI-1640
media at a concentration of 5×106 cells per mL, and 80μL
per well was incubated in 96-well tissue culture plates.
Another 20μL of ConA was added to each well, and each
sample was seeded in four wells. A working concentration
of 5μgmL −1 ConA was used for the stimulation of lympho-
cytes. After 44h of incubation at 39.5◦C in the 5% CO2 incu-
bator, 20μL of MTT (5mgmL−1) was added to each well.
The plates were incubated for another 4h, and then 100μL
of DMSO was added to each well; the plates were ﬁnally
shaken for 5min to completely dissolve the precipitate. Light
absorbance at 570nm was measured with an ELISA plate
reader (Bio-Rad Laboratories Inc., Irvine, CA).
2.8. Measurement of IgA, IgG and IBD Antibodies in Serum.
Total IgA and IgG concentrations in the sera were measured
with the Chicken IgA and IgG ELISA Quantitation Kit
(Bethyl Laboratories, Inc., Montgomery, TX) according to
the manufacturer’s instructions. The sera were diluted up to
500-fold with a sample diluent solution from the kit, and
read at 450nm in an ELISA plate reader [21]. The antibody
titer of IBDV was determined using ELISA kits (Kirkegaard
& Perry Laboratories Inc., Gaithersburg, MD), according to
the manufacturer’s instructions. Twenty microliters of buﬀer
serum from each chicken was used and read at 650nm in an
ELISA plate reader [21].
2.9. Detection of Cytokine mRNA by Semi-Quantitative RT-
PCR. The mRNA expression of the cytokines IL-2, INF-γ,
IL-4 and IL-12 was determined with a reverse transcriptional
polymerase chain reaction (RT-PCR). The housekeeping
gene, GAPDH, was used as an internal control. Periph-
eral lymphocytes were collected from the GGS-treated
and untreated groups and harvested at 24h after ConA
stimulation. Total RNA was isolated from the tissues using
the TRIzol reagent (Invitrogen Life Technologies, Carlsbad,
CA), according to the manufacturer’s instructions. The RNA
was subsequently treated with Deoxyribonuclease I (MBI
Fermentas Inc., Lithuania) to remove any genomic DNA
contamination [22]. Approximately 900ng of total RNA
was reverse-transcribed with MuLV reverse transcriptase
using the GeneAmp RNA PCR Kit (Applied Biosystems,
Foster, CA) and oligo d(T)16 primers. The RT-PCR primer
sequences and annealing conditions for IL-2, IL-4, IL-12,
INF-γ and GAPDH are listed in Table 1. The ampliﬁed RT-
PCR products were subjected to electrophoresis at 100V
in a 2% agarose gel (Invitrogen, Carlsbad, CA) for about
30min [23]. The agarose gels were stained with 0.5mgmL−1
ethidium bromide Tris/borate/EDTA buﬀer (ICN, Costa
Mesa, CA).
2.10. Statistical Analysis. The experimental data were anal-
ysed using the General Linear Model (GLM) procedure by
SAS, as described previously [24]. The diﬀerences among
herbal medicinal dosage and control groups were compared
by least mean squares comparison. Statistical signiﬁcances
were based on ∗P< .05 and ∗∗P< .01.
3. Results
3.1. Assessment of Biochemical Functions in Serum. We tested
the eﬀects of the herbal remedies on serum lipids, liver
and kidney function. Feeding the chickens a diet supple-
mented with GGS for 16 weeks had no eﬀect on body
weight or composition (data not shown). The bioactivity
indices for liver and kidney functions in the sera were
measured before and after the experiment. The GOT and
GPT were not signiﬁcantly diﬀerent between the control
and tested groups; however, the BUN concentrations were
signiﬁcantly decreased in all GGS-treated groups (P< .05),
and the CRE concentration was also decreased in the
middle-dose GGS-treated group (P< .05), indicating that
the dietary supplements of GGS modulated kidney function.
The GGS containing the active component of chlorogenic
acid (Figure 1) signiﬁcantly reduced serum cholesterol in all
three GGS-treated groups (P< .05), but had no eﬀect on the
triglycerides (Table 2).
3.2. Physical Characteristics of the Jejunum. Physical changes
were seen in the intestines of the birds that were given the
antibiotic growth promoter and health factor. The jejunum
histology and villous length of chickens fed a diet with or4 Evidence-Based Complementary and Alternative Medicine
Table 1: Oligonucleotide primer sets used for semi-quantitative RT-PCR.
RNA target Primer sets Oligonucleotide sequence Annealing temperature (◦C) Product size (bp) Accession no.
INF-γ F5  -AGCTGACGGTGGACCTATTA-3 
56 259 NM 205149
R5  -GGCTTTGCGCTGGATTCTC-3 
IL-2 F5  -CTGGGACCACTGTATGCTCT-3 
55 256 AF017645
R5  -CACCAGTGGGAAACAGTATC-3 
IL-4 F5  -ACCCAGGGCATCCAGAAG-3 
55 258 AJ621735
R5  -CAGTGCCGGCAAGAAGTT-3 
IL-12 F5  -AGACTCCAATGGGCAAATGA-3 
56 244 NM 213571
R5  -CTCTTCGGCAAATGGACAGT-3 
GAPDH F5  -GGTGGTGCTAAGCGTGTTAT-3 
56 264
R5  -ACCTCTGTCATCTCTCCACA-3 
Table 2: The eﬀects of diﬀerent supplemental dosages of GGS on
serum parameters in chickens.
Item Control group Treated groupa
SE
GGSL GGSM GGSH
GGS Dose (%, w/w) 0 0.5% 1% 2%
GOT (UL−1) 195.3 171.3 183.8 182.5 13.4
GPT (UL−1) 7.7 6.8 7.7 6.8 0.8
Cholesterol (mddL−1) 109.3 90.8∗ 83.8∗ 80.7∗ 5.9
Triglycerides (mddL−1) 27.8 33.5 21.3 24.8 6.9
BUN (mddL−1)2 . 4 1 . 9 ∗ 1.6∗ 1.6∗ 0.2
Creatinine (mddL−1) 0.28 0.23 0.20∗ 0.25 0.02
aGGSL: low dose of GGS; GGSM: medium dose of GGS; GGSH:h i g hd o s eo f
GGS.
∗Signiﬁcant diﬀerence (P< .05 versus control group).
without GGS at 16 weeks are shown in Figure 2. The villous
length was signiﬁcantly higher in the GGS-treated group
than in the control group (1250±53 versus 1603±72μm;
P< .05), indicating that dietary supplementation with GGS
is beneﬁcial to the health of the chicken.
3.3. Peripheral Lymphocyte Proliferation in Response to GGS.
To investigate the eﬀects of GGS on peripheral lymphocyte
proliferation, we collected peripheral lymphocytes from
chickenstreatedwithdiﬀerentdosagesoforallyadministered
GGS, and treated them with or without ConA in vitro.
Proliferation was measured via the MTT assay, and changes
in the proliferation ratio (ConA+/ConA–) are summarized
in Table 3. At Weeks 8, 12 and 16, peripheral lympho-
cyte proliferation in the GGSM-treated group was slightly
increased; however, proliferation in the GGSH-treated group
was signiﬁcantly higher than in the control group, by 2-3-
fold (P< .05).
3.4. Systemic Antibody Response. To evaluate the eﬀects of
GGS on the serum antibodies, the presence of natural
antibodies to IgA (Figure 3(a))a n dI g G( Figure 3(b)) in the
sera of GGS-treated and untreated birds was assessed. In
theGGSL-treatedgroup only, thesera contained signiﬁcantly
higher levels of IgA antibodies in the females than in the
control group (P< .05) (Figure 3(a)). However, there was no
Table 3: The eﬀects of supplemental GGS on peripheral lympho-
cyte proliferation in chickens of diﬀerent ages.
Groupa Dose (%, w/w)
Lymphocyte proliferation ratio
(ConA+/ConA–)
8 weeks 12 weeks 16 weeks
Control 0 1.90 2.13 1.87
GGSL 0.5 1.77 2.18 1.72
GGSM 1.0 2.40 2.68 2.79
GGSH 2.0 3.09∗ 3.76∗ 5.24∗
SE 0.34 0.31 0.52
aGGSL: Low dose of GGS; GGSM: medium dose of GGS; GGSH:h i g hd o s e
of GGS.
∗Signiﬁcant diﬀerence (P< .05 versus control group).
signiﬁcant diﬀerence in IgG antibodies between the groups
(Figure 3(b)).
3.5. Enhanced IBD Antibody Titer in Response to GGS.
Changes in the IBD antibody titers in response to GGS
are listed in Table 4. In general, the antibody titers of all
treatment groups at each time point were higher than those
of the control group, and the serum IBD antibody titers
in all groups at Week 16 were lower than those at Week
8. After vaccination, the serum antibody titers in the low-
dosage GGSL-treated groups were signiﬁcantly higher than
those of the control group (P< .05) and other treatment
groups at Week 8. At Week 16, the IBD antibody titers of
GGSL andGGSMgroupsweresigniﬁcantlyhigherthanthose
of the control group (P< .05).
3.6. Cytokine Gene Expression. Changes in cytokine expres-
sion at Week 8 are shown in Figure 4. In the IL-2 and INF-γ
networks, the IL-2 and INF-γ mRNA levels of the normal
control group were low; ConA increased their expression.
GGS increased IL-2 expression in the medium-dose groups
(P< .05), but signiﬁcantly increased IL-2 in the high-dose
group (P< .01). GGS increased INF-γ expression in a dose-
dependent manner in all groups except the low-dose group,
which demonstrated suppressed INF-γ expression. In the IL-
4 and IL-12 network, the expression of IL-4 and IL-12 wasEvidence-Based Complementary and Alternative Medicine 5
J
e
j
u
n
u
m
v
i
l
l
o
u
s
h
e
i
g
h
t
(
μ
m
)
1800
1600
1400
1200
1000
800
600
400
200
0
∗
Control
group
GGS-treated
group
1mm
(a)
(b) (c)
Figure 2: Eﬀect of GGS on jejunum. Jejunum histology and villous length of chickens fed a basal diet without GGS (control) (a) compared
to those fed a basal diet with 0.5% GGS (treatment) (b). For each intestinal section, the jejunum villous height was estimated for at least 10
individual villi in the control and GGS-treated groups, as shown by the yellow and red lines, respectively. The scale bar represents 1mm. (c)
Mean ± SE of jejunum villous height (μm) in control and treated groups. ∗P< .05.
Table 4: Theeﬀects of supplemental GGS on the IBDantibody titer
(×103) in chickens of diﬀerent ages.
Groupa Dose (%, w/w) IBD antibody titer (×103)
8 weeks 16 weeks
Control 0 5.892 5.080
GGSL 0.5 11.006∗ 8.191∗
GGSM 1.0 9.935 9.819∗
GGSH 2.0 6.831 6.640
SE 1.461 0.968
aGGSL: low dose of GGS; GGSM: medium dose of GGS; GGSH:h i g hd o s eo f
GGS.
∗Signiﬁcant diﬀerence (P< .05 versus control group).
low in the normal control group. ConA treatment increased
the level of IL-4 but not IL-12. We also observed that IL-4
was down-regulated in the low- and medium-dose groups,
and slightly increased in the high-dose GGSH-treated group.
IL-12 expression was signiﬁcantly increased in the high-dose
GGS-treated group (P< .01).
4. Discussion
GGS enhanced the IBD antibody titer at a low dose, and
promoted peripheral lymphocyte proliferation at a high
dose. GGS regulated the expression of IL-2, INF-γ,I L - 4a n d
IL-12 in the ConA-stimulated peripheral T lymphocytes.
Physical changes were observed in the intestines of birds
that were given the antibiotic growth promoter and health
factor. The growth promoter is known to inhibit normal
early microbial proliferation and, hence, the competition
for essential nutrients during the gut maturation process in
chickens [25]. In our study, GGS increased the length of the
jejunum (Figure 2), indicating that GGS could improve anti-
microbial proliferation and increase nutrition absorption.
GGS was also found to protect kidney function and to
decrease cholesterol in GGS-treated groups for a long period
of time (Table 2). All of these data suggest that GGS could
improve the health of an organism.
A traditional control strategy for IBD in broilers has
involved protection via passive immunization [4]. However,
traditional inactivated or attenuated vaccines do not provide
enoughprotectionagainsttheseantigenicvariants,whichare
very virulent (vv) IBDV [26]. Improving the eﬀectiveness of
the IBD vaccine is, therefore, an important issue. According
to our data, the low dosage GGS-treated group showed
enhanced IBD antibody titers at Week 8. The low and
medium dosage groups also had signiﬁcantly higher IBD
antibody titers than the control group at Week 16 (Table 4).
In a previous report, 1-day-old chickens were fed a diet
with or without ascorbic acid and vaccinated against IBD
at 7 days of age, and both groups were then challenged
orally with 4×105 IBDV viral particles at 21 days of age.
At 21 days of age (14 days post-vaccination) and 31 days
of age (10 days post-challenge), the number of anti-IBDV
IgG antibody secreting cells were signiﬁcantly higher in the
ascorbic acid supplemented group than in the control group
[27]. A similar study also revealed that orally administered
2% l-arginine elicited a higher antibody titer after IBDV
vaccination, and increased protection rate after IBDV chal-
lenge, when compared with the control group [28]. These6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀect of GGS on serum IgA (a) and IgG (b). The negative control (NC) group was fed with a basal diet without GGS. The levels
of serum IgA and IgG (mgdL−1) in the 0.5, 1 and 2% GGS-treated native chicken groups are shown as GGSL, GGSM and GGSH,r e s p e c t i v e l y .
Blood samples were collected at 16 weeks of age. Upper panel (M): Data from male chickens in each group. Middle panel (F): Data from
femalechickensineachgroup.Lowerpanel(M+F):Combinedmaleandfemaledata.Theasterisksrepresentsigniﬁcantdiﬀerences(P< .05)
compared with the respective control groups.
resultssuggestedthatincreasingtheanti-IBDVantibodytiter
response to IBDV vaccination would increase the protection
eﬃciency against IBDV infection. Most pathogens invade
the body of their host through mucosal surfaces, especially
those lining the gastrointestinal, respiratory and genito-
urinary tracts. Despite their phylogenetic distance, both
mammals and bird species use polymeric IgA (pIgA), which
is produced by plasma cells in the lamina propria underlying
the mucosal epithelia [29], as the primary immunological
defense against such infections. It is interesting to note that
in our study, a low dosage of GGS increased the level of
IgA in the serum of female chickens (Figure 3), indicating
that a low dosage of GGS could increase the primary
immunological defense in mucosal epithelia. We do not
yet understand why this phenomenon only appeared in the
females.
IBD causes bursal follicular lymphoid depletion, leading
to signiﬁcant reduction in humoural immune responses.
IBDV infection apparently aﬀects immature or precursor
B cells to a greater extent than mature B-lymphocytes.
The disease is a major problem in concentrated poultry
production areas throughout the world. However, it is often
not recognized because of its often subclinical presentation.
Aﬀected chickens have reduced antibody response to vac-
cinations, strong postvaccination reactions and increased
susceptibility to concurrent or secondary infections [27].
Traditional IBD vaccines have focused on stimulating the
B cells. However, recent studies that have focused on theEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Quantitative analysis of IL-2, INF-, IL-4 and IL-12 mRNA expression in cultured chicken peripheral lymphocytes treated with
diﬀerent GGS doses at 24h after ConA stimulation. (a) Representation of mRNA expression by semi-quantitative RT-PCR analysis. Mr.:
100-bp ladder of DNA markers; NC: normal cultured chicken peripheral lymphocytes (Week 8) without ConA stimulation; –: no GGS;
GGSL: low-dose GGS treatment group; GGSM: medium-dose GGS treatment group; GGSH: high-dose GGS treatment group. The results are
representative of three experiments. (b) The relative mRNA expression levels in control and diﬀerent GGS-treated groups were quantiﬁed
by a densitometer. The signal from GAPDH RT-PCR products in each sample was used as an internal control in each mRNA calculation.
∗P< .05; ∗∗P< .01.
importance of T cells in IBDV pathogenesis, have shown
that cell-mediated immunity may be more important in
IBDV infections than previously thought [30, 31]. Our data
show that a high dose of GGS can improve peripheral T
lymphocyte proliferation in response to ConA stimulation
andcanincreasetheproliferationrateofthesecellsinatime-
dependent manner beginning at Week 8 (Table 3).
Interleukin-2 (IL-2), initially known as a T-cell growth
factor, is a powerful immuno-regulatory lymphokine that is
produced by lectin- or antigen-activated T cells [8, 32, 33]. It
issecretedbymatureTlymphocytesuponstimulation,andis
constitutively secreted by certain T-cell lymphoma cell lines.
Chicken IL-2 (ChIL-2) may enhance immunity against avian
pathogens, which would introduce a new weapon for the
control of infectious diseases in poultry. The administration
of the IBD vaccine with ChIL-2 provided better protection
than vaccination alone [8]. Previous reports showed that
the simultaneous injection of chicken IL-2 plasmid DNA
with the IBD vaccine signiﬁcantly increased protection after
challenge with the virulent strain [32, 33]. These results
strongly indicate that the eﬃcacy of the avian DNA vaccine
could be modulated by the co-administration of a plasmid
encodingChIL-2.Inthisstudy,wefurtherdemonstratedthat
a high-dose of GGS strongly enhanced ConA-induced ChIL-
2. Therefore, GGS could improve the eﬃciency of the IBD
vaccine. Furthermore, immune cells and immune molecules
can mutually regulate one another and form many immune
regulation networks. The IL-2-IFN-γ-NKC system is one
suchimmune regulation network. In this network, IL-2 plays
an important role in regulating the generation of IFN-γ and
the activity of natural killer cells (NKC). IFN-γ also partic-
ipates in the immune response mediated by T cells, B cells
and other immune cells [34]. IFN-γ severely restricts virus
replication and can even cure persistently infected bovine8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Proposed mechanism of GGS functions in immunity
enhancement. High-dose of GGS (GGSH) administration will
increase IL-2, IL-4 and IL-12 expression from antigen presenting
cells(APC)tostimulatena¨ ıveTcellsdiﬀerentiation.Administration
of a medium dose of GGS (GGSM)a sw e l la sG G S H will enhance
IFN-γ expression to stimulate T-helper 1 (Th1) cells diﬀerentiation
and cytotoxic T lymphocytes (CTL) function. Administration of
a low-dose of (GGSL) will further increase B lymphocytes (BL)
producing speciﬁc antibodies.
epithelial cells [35]. Our study showed that the medium- and
high-dose GGS-treated groups not only exhibited increased
expression of IL-2 mRNA, but also increased expression
of IFN-γ mRNA (Figure 4). Chlorogenic acid is the most
abundant compound in the GGS. In the previous study, it
wasfoundthatchlorogenicacidcouldenhancetheactivityof
human lymphocyte proliferation and IFN-γ secretion [36].
Thus,itisproposedthatGGSstrengthenedimmunityviathe
mechanism outlined in Figure 5.
In mammals, it has been known for some time that
the balance between the Th1 and Th2 lymphocyte subsets
determines susceptibility to some disease states. Thus, an
unusually dominant Th1 response is often associated with
autoimmunity, while improper development of Th2 immu-
nity can lead to allergic diseases [37]. Chicken Th2 cells
are necessary to induce the humoural response to combat
parasite invasion [38]. As in mammals, the chicken genome
contains a cluster of Th2 cytokine genes containing IL-4
and other cytokines that are expressed in lymphoid tissues.
Activation of this gene cluster is associated with down-
regulating the inﬂammatory (Th1) response and, as a result,
drives Th2 cell development [38]. Unlike IL-4, IL-12 is able
to facilitate the proliferation and activation of Thl cells and
the production of IL-2 and IFN-γ [39]. IL-12 induces IFN-
γ synthesis by neonatal CD4T-cells. Additionally, IL-2 can
further synergise with IL-12 to trigger IFN-γ production
[40, 41]. Our data demonstrate that GGS-treated chickens
produced more IL-12 than IL-4, and that IL-2 and INF-γ
were also up-regulated. The results reveal that GGS can skew
the lymphocyte subset development towards Th1 ratherthan
Th2 cells.
In conclusion, our results show that GGS-enhanced cell-
mediated immunity and assisted the IBD vaccine, strength-
ening the anti-viral functions. Since the chicken’s immune
system is similar to that of mammals, chickens provide an
attractive model system to study the eﬀectiveness of GGS
supplements in controlling diseases in livestock and human
beings. Nevertheless, additional investigations are required
to determine the potential clinical utility of GGS as an
immunopotentiator in infant vaccination programmes. The
pharmaceutical technology of TCM as applied in animal
health care is relatively simple, and its production costs are
relatively low.
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